PTEN and neoplasm: Further studies with additional melanoma mouse models where tumor growth is driven by different mutations such as the BrafV600E-Pten-/- model,47 along with the use of mouse models that allow for the ablation of specific DC subsets should evaluate the potential of the different DC subsets in both tumors and tumor-draining LNs in driving T cell responses during immunotherapy.